<DOC>
	<DOCNO>NCT02357342</DOCNO>
	<brief_summary>Phase 2 clinical trial , single site , randomize , subject-masked study determine safety efficacy intravitreal injection Sirolimus subject wet Age-Related Macular Degeneration ( wet AMD ) persistent intraretinal subretinal edema due neovascular AMD despite previous Anti-VEGF treatment .</brief_summary>
	<brief_title>Sirolimus Versus AntiVEGF Wet AMD</brief_title>
	<detailed_description>Thirty subject randomize receive intravitreal Sirolimus standard care treatment 1:1 ratio . Over course six month trial plus 6 month optional extention , subject evaluate monthly . Treatment Sirolimus give baseline , month 2 month 4 sham injection give month 1 , 3 5 . For subject extension Sirolimus also give month 6 , 8 10 sham month 7 , 9 , 11 . Subjects standard care group receive anti-VEGF injection sham monthly . Retreatment criterion base upon continued subretinal edema , intraretinal edema active chorioretinal neovascularization ( CNV )</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>best correct visual acuity 565 , inclusive , study eye presence choroid neovascularization secondary AMD persistent edema despite least 3 previous intravitreal antiVEGF injection past 5 month great 100 micron decrease central subfield thickness OCT since last standard care visit history major ophthalmic surgery study eye past 3 month history significant ocular disease condition exudative AMD may confound result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>